These guidelines are intended for use in all centres in the South East London Cancer Network (SELCN).
Diagnostic and treatment services will be organised along the lines suggested in the NICE Improving Outcomes Guidance document
1. The main points in this document were:
1) Provision of an integrated and reviewed diagnostic report.
2) Treatment decisions taken by multidisciplinary teams.
3) Inpatient treatment provided in centres meeting appropriate standards.
More detailed information on the configuration of these services can be found in the SELCN operational policies document.
Sources
Diagnostic categories and criteria are based on the WHO classification of haematological malignancies
2 supplemented by material derived from published papers and guidelines, the Haematological Malignancy Diagnostic Service in Leeds (
www.hmds.org.uk) and the views of the members of the SELCN haemato-oncology TWG.
Treatment guidelines have been derived from:
1) Previously published material from bodies such as BCSH and UKMF
2) Published randomised trials
3) Ongoing NCRN clinical trials
4) NICE guidance
5) Consensus amongst SELCN haematologists
The document is intended for guidance and although every effort to achieve accuracy has been made, responsibility for decisions about diagnosis and treatment remain the responsibility of individual physicans and MDTs.
Minimum dataset
Data will be collected on MDM proformas, a copy of which will be held by the Network clinical lead. It is envisaged that a database of this information will be developed at network level.
Research and Clinical Trials
Where appropriate patients will be entered into NCRN badged clinical trials. A summary of and links to the relevant trials are given as required along with brief details where relevant. SELCN maintains a database of clinical trials active within SELCN.
In addition to NCRN approved clinical trials, a variety of commercially sponsored and investigator initiated phase 1 and 2 studies are underway within the network. Where these are relevant to individual disorders these will be highlighted.
Tissue banking for various disorders is also underway and clinicans will be contacted by the investigators responsible for this as appropriate.
chronic myeloid leukaemia.pdf
